Literature DB >> 17208548

Ex utero intrapartum treatment with extracorporeal membrane oxygenation for severe congenital diaphragmatic hernia.

Shaun M Kunisaki1, Carol E Barnewolt, Judy A Estroff, Laura B Myers, Dario O Fauza, Louise E Wilkins-Haug, Ian A Grable, Steven A Ringer, Carol B Benson, Luanne P Nemes, Donna Morash, Terry L Buchmiller, Jay M Wilson, Russell W Jennings.   

Abstract

PURPOSE: The purpose of this study was to determine whether ex utero intrapartum treatment with extracorporeal membrane oxygenation (EXIT to ECMO) is a reasonable approach for managing patients antenatally diagnosed with severe congenital diaphragmatic hernia (CDH).
METHODS: A 6-year retrospective review was performed on fetuses with severe CDH (liver herniation and a lung/head ratio <1.4, percentage of predicted lung volume <15, and/or congenital heart disease). Fourteen of the patients underwent EXIT with a trial of ventilation. Fetuses with poor preductal oxygen saturations despite mechanical ventilation received ECMO before their delivery. Maternal-fetal outcomes were analyzed.
RESULTS: There were no maternal-reported complications. Three babies passed the ventilation trial and survived, but 2 of them required ECMO within 48 hours. The remaining 11 fetuses received ECMO before their delivery. Overall survival after EXIT-to-ECMO was 64%. At 1-year follow-up, all survivors had weaned off supplemental oxygen, but 57% required diuretics and/or bronchodilators.
CONCLUSION: This is the largest reported experience using EXIT to ECMO in the management of severe CDH. The EXIT-to-ECMO procedure is associated with favorable survival rates and acceptable pulmonary morbidity in fetuses expected to have a poor prognosis under conventional management.

Entities:  

Mesh:

Year:  2007        PMID: 17208548     DOI: 10.1016/j.jpedsurg.2006.09.009

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

1.  A Modified EXIT-to-ECMO with Optional Reservoir Circuit for Use during an EXIT Procedure Requiring Thoracic Surgery.

Authors:  Gregory S Matte; Kevin R Connor; Nathalia A Toutenel; Danielle Gottlieb; Francis Fynn-Thompson
Journal:  J Extra Corpor Technol       Date:  2016-03

2.  Management of Congenital Diaphragmatic Hernia in Newborn - Paradigm Shift and Ethical Issues.

Authors:  Sushmita Nitin Bhatnagar; Yogesh Kumar Sarin
Journal:  Indian J Pediatr       Date:  2017-06-16       Impact factor: 1.967

3.  Ex utero intrapartum treatment for giant congenital omphalocele.

Authors:  Xu-Yong Chen; Ji-Xin Yang; Hong-Yi Zhang; Xiao-Feng Xiong; Khalid Mohamoud Abdullahi; Xiao-Juan Wu; Jie-Xiong Feng
Journal:  World J Pediatr       Date:  2018-03-05       Impact factor: 2.764

Review 4.  Modern fetal surgery-a historical review of the happenings that shaped modern fetal surgery and its practices.

Authors:  Lauren L Evans; Michael R Harrison
Journal:  Transl Pediatr       Date:  2021-05

5.  Human induced pluripotent stem cell-derived lung organoids in an ex vivo model of the congenital diaphragmatic hernia fetal lung.

Authors:  Shaun M Kunisaki; Guihua Jiang; Juan C Biancotti; Kenneth K Y Ho; Briana R Dye; Allen P Liu; Jason R Spence
Journal:  Stem Cells Transl Med       Date:  2020-09-19       Impact factor: 6.940

Review 6.  Intraoperative management for ex-utero intrapartum treatment: focusing on the fetus.

Authors:  Woosuk Chung; Chaeseong Lim
Journal:  Anesth Pain Med (Seoul)       Date:  2021-10-29

7.  EXIT procedure in twin pregnancy: a series of three cases from a single center.

Authors:  Lutgardo García-Díaz; Juan Carlos de Agustín; Antonio Ontanilla; Maria Luisa Marenco; Antonio Pavón; Antonio Losada; Guillermo Antiñolo
Journal:  BMC Pregnancy Childbirth       Date:  2014-07-30       Impact factor: 3.007

8.  Maternal complications following open and fetoscopic fetal surgery: A systematic review and meta-analysis.

Authors:  Adalina Sacco; Lennart Van der Veeken; Emma Bagshaw; Catherine Ferguson; Tim Van Mieghem; Anna L David; Jan Deprest
Journal:  Prenat Diagn       Date:  2019-02-27       Impact factor: 3.050

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.